Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Intrathecal Tominersen in Early Manifest Huntington's Disease
NCT02519036Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Nov 2017
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 3
01
Overview
A Phase 2 trial of tominersen in Huntington's disease (HD), sponsored by Ionis Pharmaceuticals. Started Aug 2015; status: completed.
02
Drugs
tominersen
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02519036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02519036.